Prosecution Insights
Last updated: November 15, 2026

BLIRT S.A.

Technology area: Biotechnology & Pharmaceuticals

3 pending office actions • 2 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready

Analysis

BLIRT S.A. has 2 pending office actions in Biotechnology & Pharmaceuticals. The matters are assigned to 2 examiners and 2 art units, indicating separate examination paths.

DICKENS, AMELIA NICOLE is the busiest examiner, with 1 pending matter. Counsel should address each record independently while keeping scientific terminology and descriptions of the claimed biotechnology consistent where the applications share subject matter.

Written from this page's own data; every figure is computed from USPTO records and verified before publication.

Portfolio Summary

3
Total Pending OAs
2
Non-Final OAs
1
Final Rejections
0
Advisory / Quayle

Response Deadline Pressure

Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.

0
Overdue
0
Due this week
1
Due this month
0
Due in next 60 days
0
Due later

Case Difficulty Mix

Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.

3
Hard (100%)
0
Medium (0%)
0
Easy (0%)
0
Unknown (0%)

Rejection Statute Mix

BucketCases
Multi-statute (no §101)3 (100%)

Industry Mix

How the docket's pending cases split across USPTO tech-center bands.

3
Life Sciences
100% of docket
0
Information Tech
0% of docket
0
Communications
0% of docket
0
Semiconductors
0% of docket
0
Mechanical / Eng
0% of docket
0
Business / Other
0% of docket

Time-on-OA Estimate

Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.

30 h
Manual time on pending OAs
6 h
Time saved (low, 20%)
10 h
Time saved (mid, 35%)
0.3 wks
FTE-weeks freed (mid)

Top Examiners on this docket

ExaminerApps on this docketAllow rateInterview lift
DICKENS, AMELIA NICOLE 1 47.7% +22.5%
EIX, EMILY FAY 1 45.9% +73.9%
KOROTCHKINA, LIOUBOV G 1 29.0% +64.1%

Hard Cases (3)

Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 3 ordered by deadline are shown.

App #TitleExaminerDue in
18035143 PRODUCTION AND USE OF A FREEZE-DRIED OR READY-FOR-LYOPHILIZATION HUMAN RNASE INHIBITOR EIX, EMILY FAY 8d
18711923 TRITIRACHIUM ALBUM PROTEINASE K MUTANT AND ITS ZYMOGEN, EXPRESSION PLASMID, RECOMBINANT PICHIA PASTORIS STRAIN AND METHOD OF PRODUCING THE MATURE FORM OF PROTEINASE K MUTANT DICKENS, AMELIA NICOLE —
17642697 A NEW, NON-SPECIFIC THERMOLABILE NUCLEASE ACTIVE AT LOW TEMPERATURE, IN WIDE PH RANGE AND HIGH CONCENTRATION IN SALTS KOROTCHKINA, LIOUBOV G —

Interview Candidates (3)

Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.

App #TitleExaminerDue in
18035143 PRODUCTION AND USE OF A FREEZE-DRIED OR READY-FOR-LYOPHILIZATION HUMAN RNASE INHIBITOR EIX, EMILY FAY 8d
18711923 TRITIRACHIUM ALBUM PROTEINASE K MUTANT AND ITS ZYMOGEN, EXPRESSION PLASMID, RECOMBINANT PICHIA PASTORIS STRAIN AND METHOD OF PRODUCING THE MATURE FORM OF PROTEINASE K MUTANT DICKENS, AMELIA NICOLE —
17642697 A NEW, NON-SPECIFIC THERMOLABILE NUCLEASE ACTIVE AT LOW TEMPERATURE, IN WIDE PH RANGE AND HIGH CONCENTRATION IN SALTS KOROTCHKINA, LIOUBOV G —

Top Art Units

Art UnitApps
1653 2
1645 1

Pending Office Actions

App #TitleExaminerArt UnitStatutesStatusDue inAIFiled
18711923 TRITIRACHIUM ALBUM PROTEINASE K MUTANT AND ITS ZYMOGEN, EXPRESSION PLASMID, RECOMBINANT PICHIA PASTORIS STRAIN AND METHOD OF PRODUCING THE MATURE FORM OF PROTEINASE K MUTANT DICKENS, AMELIA NICOLE 1645 §102§112 Non-Final OA — Pending May 21, 2024
18035143 PRODUCTION AND USE OF A FREEZE-DRIED OR READY-FOR-LYOPHILIZATION HUMAN RNASE INHIBITOR EIX, EMILY FAY 1653 §102§103 Final Rejection 8d Pending May 03, 2023
17642697 A NEW, NON-SPECIFIC THERMOLABILE NUCLEASE ACTIVE AT LOW TEMPERATURE, IN WIDE PH RANGE AND HIGH CONCENTRATION IN SALTS KOROTCHKINA, LIOUBOV G 1653 §103§112Other Non-Final OA — Pending Mar 13, 2022

Managing BLIRT S.A.'s Patent Portfolio?

IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Frequently Asked Questions

How many pending USPTO office actions does BLIRT S.A. have?

BLIRT S.A. has 3 pending office actions as of November 2026, spread across 2 art units and 3 examiners.

Which USPTO examiner handles the most BLIRT S.A. applications?

Amelia Nicole Dickens has the most, with 1 of BLIRT S.A.'s pending office actions.

What technology area are BLIRT S.A.'s patent applications in?

Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month